Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple sclerosis (MS). During the third quarter ended September 30, 2024, the firm advanced both its phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and a twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) looking at orally available lead asset, nuclear receptor related 1 (Nurr1) activator, IMU-838.
Immunic Phase 3 MS study advances following positive recommendation from independent committee
Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple sclerosis (RMS). The company said an Independent Data Monitoring Committee (IDMC) reviewed unblinded data and concluded that the trials had not met futility criteria, recommending that the study continue as planned without any changes.
Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress
Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which has highlighted its therapeutic potential in multiple sclerosis (MS). Vidofludimus calcium consistently reduced neurofilament light chain (NfL) levels in the Phase 2 CALLIPER trial, suggesting it may slow disease progression across all progressive MS subtypes, the company reported.
Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being supplied for an investigator-sponsored Phase 2 clinical trial focused on treating post-COVID syndrome (PCCS).
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial
Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead asset vidofludimus calcium for post-COVID syndrome. The RAPID_REVIVE study is sponsored by Goethe University Frankfurt, Germany, with funding received via a grant from the German Federal Ministry of Education and Research.
Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D Day
Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September 10 featuring discussions on the company's lead drug asset vidofludimus calcium potential as a treatment for both relapsing and progressive MS patients. The company's management team, including CEO Daniel Vitt, COO Jason Tardio, chief medical officer Andreas Muehler, and chief scientific officer Hella Kohlhof will be joined by MS industry experts to discuss the MS space and vidofludimus calcium's promise.
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Jessica Breu - VP, IR & Communications Daniel Vitt - CEO Glenn Whaley - CFO Jason Tardio - COO Conference Call Participants Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Thalmann Tom Smith - Leerink Partners Tyler Bussian - Brookline Madison El-Saadi - B. Riley Jessica Breu Good morning, and welcome to Immunic's Second Quarter 2024 Earnings Call.
Immunic strengthens leadership team as MS trials advance toward key milestones
Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and the subsequent period. The biotechnology firm has welcomed experienced multiple sclerosis drug commercialization executive Jason Tardio as its chief operating officer and president and appointed senior pharmaceutical executive Simona Skerjanec to its board of directors.
Immunic chief scientific officer shares insights on innovative MS therapy - ICYMI
To mark World Brain Day on July 22, Immunic Inc (NASDAQ:IMUX)'s chief scientific officer Hella Kohlhof joined Proactive to discuss the company's lead asset vidofludimus calcium which is being developed to treat the neurological disease multiple sclerosis (MS). She highlighted that this drug has a dual mode of action, with neuroprotection, anti-inflammatory, and antiviral properties.
Immunic appoints Simona Skerjanec to board of directors
Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors. Skerjanec brings nearly three decades of experience in drug development and commercialization, having held senior roles at top pharmaceutical companies.
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal efforts to prepare for the potential launch of vidofludimus calcium. Jason Tardio will join the company in the newly created role of COO and president from July 12, the biotechnology company said.
Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases
Nvidia Corp is set to dominate market discussions this week as it prepares to release its earnings report on Wednesday afternoon. The semiconductor giant, with a market cap of approximately $2.3 trillion, holds significant influence in the S&P 500. Its performance is expected to impact the technology sector and broader market indices. "As Nvidia goes, so go most of the semiconductor stocks and AI plays," is how Jay Woods, chief global strategist at Freedom Capital Markets (NASDAQ:FRHC), put it. He noted that the stock's average post-earnings move is plus 8.5%, making it a critical factor for market volatility. Analysts ratings, based on Bloomberg statistics, have the equivalent of 61 buys, 7 holds and 0 sells on the stock. The average analyst price target is $1018.45 which is less than a 10% upside from current levels. “While a disappointment could open the door for many potential downgrades, a beat should lead to a wave of price target upgrades,” said Woods. Beyond Nvidia, other major earnings include Lowe’s, Target, Toll Brothers, elf Beauty, and Macy’s. Zoom Video and Palo Alto Networks are also in focus, with their earnings reports potentially adding to market movements. Zoom Video, which has been struggling since its peak, needs to show sustained improvement while Palo Alto Networks aims to recover from recent declines despite a strong track record, according to Woods. On the macro front The week also features significant economic data releases. Existing Home Sales and FOMC minutes on Wednesday, Jobless Claims and New Home Sales on Thursday, and Durable Goods and Consumer Sentiment on Friday will provide insights into the economic landscape. The S&P 500 reached new highs last week, driven by a cooler-than-expected CPI number, which fueled optimism about potential Fed rate cuts. However, the 10-year yield remains stable above key technical levels, maintaining caution among traders. Freedom Capital Markets (NASDAQ:FRHC) notes the market's anticipation for the Fed minutes, which will reveal any divisions among committee members regarding future rate hikes or cuts. The consensus is no action in June, with possible rate cuts discussed for July or September. Click here to subscribe to future Freedom weekly newsletters by Jay Woods.
